Additional file 4: of Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Table presenting “Common, all-causality adverse events reported in patients with OS ≥24 versus <24 months in the placebo titration arm.” (PDF 73 kb)